Alto Neuroscience (ANRO) Other Non-Current Liabilities (2023)
Alto Neuroscience's (ANRO) quarterly Other Non-Current Liabilities came in at $1.4 million in Q4 2023, down 3.43% quarter-over-quarter from $1.4 million in Q3 2023.
Alto Neuroscience (ANRO) Other Non-Current Liabilities (2023) Analysis & Trends
Alto Neuroscience has disclosed Other Non-Current Liabilities across 1 years of filings, most recently posting $1.4 million for Q4 2023.
- Other Non-Current Liabilities for Q4 2023 came in at $1.4 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $1.4 million (changed N/A YoY), and the FY2023 annual result was $1.4 million, changed N/A from the prior year.
- Other Non-Current Liabilities came in at $1.4 million for Q4 2023 at Alto Neuroscience, down from $1.4 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $1.7 million in Q1 2023 to a low of $1.4 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Alto Neuroscience | 643.06 Mn | 379.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.35 Mn |
| Sep 30, 2023 | 1.40 Mn |
| Jun 30, 2023 | 1.60 Mn |
| Mar 31, 2023 | 1.70 Mn |